How many drugs treat Chronic kidney disease?

Drug Landscape tracks 5 marketed treatments for Chronic kidney disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Chronic kidney disease?

Most recent: Farxiga — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-kidney-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic kidney disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic kidney disease (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic kidney disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Farxiga	DAPAGLIFLOZIN	AstraZeneca	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2014-01-01
DAPA	DAPA	Astrazeneca Ab		Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Forxiga	Forxiga	AstraZeneca Turkey		Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Farxiga	Farxiga	AstraZeneca		Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Dapaglifozin	Dapaglifozin	MedImmune LLC		Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 2 drugs in Chronic kidney disease
AstraZeneca Turkey · 1 drug in Chronic kidney disease
Astrazeneca Ab · 1 drug in Chronic kidney disease
MedImmune LLC · 1 drug in Chronic kidney disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic kidney disease:

Cite this brief

Drug Landscape (2026). Chronic kidney disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-kidney-disease. Accessed 2026-06-10.

Chronic kidney disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing